Rationale: In the past decade, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) treatment had been an important therapy for treating advanced EGFR-mutated lung cancer patients. However, a large number of these patients with EGFRTKIs treatment always acquired resistance to these drugs in one year. The histologic transformation is an important resistance mechanism.
Introduction
Cancers are the leading causes of death worldwide, over 20% of these dead people are related to lung cancer. [1] In the past decade, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) treatment had been an important therapy for treating advanced lung cancer patients. However, a large number of these patients with EGFR-TKIs treatment always acquired resistance to these drugs in 1 year. [2] [3] [4] The histologic transformation is an important resistance mechanism. [5] [6] [7] Some cases have been reported that lung adenocarcinoma could transform into small cell lung cancer or squamous cell carcinoma after treatment of EGFRTKIs. [6] [7] [8] [9] As far as we know, there is no report mentioning that lung adenocarcinoma transforms into both small-cell lung cancer (SCLC) and squamous cell carcinoma (SCC) in a same patient.
Here we report a case of EGFR-mutated lung adenocarcinoma that showed histologic transformation to both SCLC and SCC after treatment of gefitinib.
Case report
In August 2014, a 41-year-old male smoker was admitted to our hospital because of right pleural effusion. After obtaining the patient's informed consent, medical thoracoscopy examination was performed and many parietal pleural nodules were found in right lung. Histopathologic examination showed low differentiated adenocarcinomas in parietal pleural nodules which considered to be metastases rather than the primary tumor (Fig. 1) . Molecular testing using FISH was carried out on these parietal pleural nodules and found to be EGFR positive (exon 19 deletion). Considering the cancer was EGFR mutated, the patient began to receive treatment with 250 mg gefitinib daily since Unfortunately, the chest computed tomography in November 2015 revealed the lesions in right lung became larger and new lesions were found in the left lung. Without the doctor's advice, the patient tried Tarceva, Sorafenib, BIBW2992, AZD9291, XL184, and Crizotinib successively. However, there was no obvious curative effect and the tumor gained progress. In February 2017, the patient was admitted to our hospital again. Positron emission tomography-computed tomography revealed that a mass in the right hilus pulmonis and multiple nodules in the bilateral lungs with high glycometabolism, which were considered to be primary cancer or metastases. After obtaining the patient's informed consent, a lung puncture biopsy under computed tomography guidance of the right lung mass was performed. Histopathologic examination showed small cell lung cancer ( Fig. 2) and the patient began to receive treatment with chemotherapy (etoposide 0.1 g day2-5 + cis-platinum 30 mg day2-4). Unfortunately, the chemotherapy treatment did not work and the right lung mass became larger. In order to get the latest pathology, a bronchoscopy was performed after obtaining the patient's informed consent. Interestingly, histopathologic examination showed squamous cell carcinoma (Fig. 3) . The patient died in April 2017 that survived for 32 months from lung cancer was found for the first time.
Discussion
Lung cancers harboring EGFR mutations respond to EGFRTKIs. But patients with EGFR-TKIs treatment always acquired drug assistance in 1 year. To date, a variety of acquired resistance mechanisms have been reported, including secondary EGFR resistance mutations (T790M), MET amplification, histologic transformation to SCLC and so on. [3] In some reports, histologic transformation from adenocarcinoma to SCC also had been described as a mechanism of resistance to the EGFR-TKIs, but the mechanism of such histological transformation remains unclear. [3, [6] [7] [8] [9] In our case, the patient was found with adenocarcinoma harboring EGFR mutation at first and responded to gefitinib well. However, the patient acquired drug resistance to gefitinib after 11 months of treatment. At last, the histopathologic examination showed the patient had both SCLC and SCC, while adenocarcinoma cell was not found. It was hard to distinguish the changed histopathology was made by the histologic transformation or it existed from the start, though the immunohistochemistry was performed. It is unclear why the histological changed from adenocarcinoma to both SCLC and SCC. It was possible that the tumor was initially a mixed histological type such as adenosquamous carcinoma with SCLC, all types of cells coexisted in the original tumor mass, but only SCC and SCLC remained after the treatment. The second possibility was that the tumor was initially an adenosquamous carcinoma that the adenocarcinoma transformed to SCLC under the pressure of gefitinib treatment. The third possibility was that the tumor was initially a mixed histological type of adenocarcinoma and SCLC that the adenocarcinoma transformed to SCC. Even it was possible that Medicine the tumor was initially only adenocarcinoma and transformed to both SCLC and SCC after the treatment. Disappointingly, the first histopathologic examination specimens were parietal pleural nodules which were considered to be metastases rather than the primary tumor, which means it was hard to confirm which of the above conjectures was right. We also acknowledge that it is hard to rule out the possibility that whether the post-gefitinib treatment patient tried without the doctor's advice made a difference in histologic transformation or pathological selection.
Conclusion
To the best of our knowledge, it is the first case of EGFR-mutated lung adenocarcinoma transforming to both SCLC and SCC which was treated with and responded to gefitinib. The patient did not receive effective treatment after gefitinib resistance occurred. To help establish the best treatment for these patients, further studies are in need.
